SCHEMBL227491

SCHEMBL227491

Cc1ccccc1C(O)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.65
CYP2C9 P11712 2/20 0.53
MEN1 O00255 1/20 0.53
MAPT P10636 1/20 0.53
KMT2A Q03164 1/20 0.53
ACP3 P15309 1/20 0.53
ESR1 P03372 1/20 0.46
OPRM1 P35372 4/20 0.42
CYP2D6 P10635 2/20 0.42
ADRA2A P08913 2/20 0.42
SLC22A2 O15244 1/20 0.42
SLC22A1 O15245 1/20 0.42
GRIN2D O15399 1/20 0.42
GRIN3B O60391 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42
ADRA2B P18089 1/20 0.42
CHRM3 P20309 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3858791 1.00 GAA (0.65) GAACYP2C9MEN1MAPTKMT2A
SCHEMBL28973546 1.00 GAA (0.65) GAACYP2C9MEN1MAPTKMT2A
Acetic Acid SCHEMBL28093893 0.92 GAA (0.57) GAACYP2C9MEN1MAPTKMT2A
SCHEMBL8805155 0.87 GAA (0.56) GAACYP2C9MEN1MAPTKMT2A
SCHEMBL30598699 0.87 GAA (0.61) GAACYP2C9MEN1MAPTKMT2A
SCHEMBL598722 0.85 GAA (0.57) GAACYP2C9MEN1MAPTKMT2A
SCHEMBL8496291 0.85 GAA (0.54) GAACYP2C9MEN1MAPTKMT2A
SCHEMBL21247060 0.85 GAA (0.50) GAACYP2C9MEN1MAPTKMT2A
SCHEMBL11603883 0.84 ACP3 (0.55) GAACYP2C9MEN1KMT2AACP3
SCHEMBL8497190 0.84 CYP2C9 (0.49) GAACYP2C9MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113402770-B Method for degrading, recycling and reusing polyurethane 上海鹤城高分子科技有限公司 2023-03-24 CN claimed
CN-112517060-B Catalyst, application and synthesis method of 4-hydroxycoumarin derivative 山东农业大学 2022-03-25 CN claimed
CN-113402770-A Method for degrading, recycling and reusing polyurethane 上海鹤城高分子科技有限公司 2021-09-17 CN claimed
EP-3254860-B1 RECORDING MATERIAL AND RECORDING SHEET NIPPON SODA CO (JP) 2020-11-04 EP claimed
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
US-20020137816-A1 Phase change inks XEROX CORPORATION 2002-09-26 US claimed
EP-0677076-B1 DIARYL CARBINOL METATHESIS CATALYSTS SHELL OIL CO (US) 1997-04-16 EP claimed
EP-0677076-A1 DIARYL CARBINOL METATHESIS CATALYSTS. SHELL OIL CO (US) 1995-10-18 EP claimed
WO-1994015989-A1 DIARYL CARBINOL METATHESIS CATALYSTS SHELL OIL COMPANY (US) 1994-07-21 WO claimed
US-5276118-A Metal complex SHELL OIL COMPANY (US) 1994-01-04 US claimed
US-3968147-A COORDINATION CATALYST MONSANTO COMPANY (US) 1976-07-06 US claimed
WO-2024213709-A1 COMPOSITIONS FOR LITHIUM-ION BATTERY ELECTRODES, ELECTRODES AND BATTERIES USING SAID COMPOSITIONS ARKEMA FRANCE (FR) 2024-10-17 WO disclosed
EP-4447148-A1 COMPOSITIONS FOR LITHIUM-ION BATTERY ELECTRODES, ELECTRODES AND BATTERIES USING SAID COMPOSITIONS ARKEMA FRANCE (FR) 2024-10-16 EP disclosed
US-20240336645-A1 METALLOCENE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF PETROCHINA COMPANY LIMITED (CN) 2024-10-10 US disclosed
EP-4406978-A1 METALLOCENE COMPOUND, PREPARATION METHOD AND USE PetroChina Company Limited (CN) 2024-07-31 EP disclosed
EP-0350309-B1 PIPERIDINE DERIVATIVES Pfizer Limited (GB) 1992-11-11 EP disclosed
US-5089505-A Anticholinergic agents PFIZER INC. (US) 1992-02-18 US disclosed
CN-1039415-A New 1, the preparation method of 3-3-disubstituted piperidine derivatives PFIZER (GB) 1990-02-07 CN disclosed
EP-0350309-A1 Piperidine derivatives Pfizer Limited (GB) 1990-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240336645-A1 METALLOCENE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF CPNE4, ZC3HAV1L, ZRANB2 GAA 3850/4885CYP2C9 2791/4885MEN1 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.